Engineered immune cells take aim at rare Organ-Damaging disease
NCT ID NCT07626476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized cell therapy called BCMA-targeted CAR-T cells in 30 adults with relapsed or refractory light chain amyloidosis, a rare disease where abnormal proteins build up in organs. The treatment uses the patient's own immune cells, modified to attack the cells producing those proteins. The main goals are to check safety and see if it can reduce disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BCMA-targeted CAR-T cells (a personalized immune cell therapy made from the patient's own blood)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat light chain amyloidosis, potentially reducing harmful protein buildup in organs.
- What could go wrong
- This is a very early, small trial (30 people) focused on safety. CAR-T therapy can cause serious side effects like cytokine release syndrome and infections. It may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, Fengtai District, 100070, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Targeting antibody stop amyloid buildup in its tracks?
- Can a radioactive peptide spot hidden amyloid in the heart?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Nationwide registry aims to crack the code of a rare protein-clogging disease
- Gene-Guided Chemo-Free strategy targets AL amyloidosis
- New scan spots hidden organ damage before symptoms start